<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salahuddin, Salman</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">FINEARTS-HF: Improving outcomes in heart failure with preserved or mildly reduced ejection fraction</style></title><secondary-title><style face="normal" font="default" size="100%">Cleveland Clinic Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">273-277</style></pages><doi><style  face="normal" font="default" size="100%">10.3949/ccjm.93a.25081</style></doi><volume><style face="normal" font="default" size="100%">93</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">The FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure, N Engl J Med 2024; 391(16):1475–1485) trial evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in patients with left ventricular ejection fraction 40% or greater. Finerenone reduced the composite risk of hospitalization for heart failure or cardiovascular death by 16% relative to placebo (rate ratio 0.84, P = .007), primarily by lowering admissions for heart failure. Finerenone is the first mineralocorticoid receptor antagonist to improve outcomes in this patient population.</style></abstract></record></records></xml>